miglustat dipharma
dipharma arzneimittel gmbh - miglustaattia - gaucherin tauti - muut ruoansulatuskanavan ja aineenvaihduntatuotteet - miglustaatti dipharma on tarkoitettu suun hoito aikuisten lievän ja keskivaikean tyypin 1 gaucher ' n tautia. miglustaatti dipharma voidaan käyttää vain potilaille, joille entsyymikorvaushoito ei sovi. miglustaatti dipharma on tarkoitettu hoitoon progressiivinen neurologiset oireet aikuisilla ja lapsilla, joilla oli niemann-pickin tyypin c tautia.
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
voriconazol accordpharma 200 mg infuusiokuiva-aine, liuosta varten
accord healthcare b.v. - voriconazole - infuusiokuiva-aine, liuosta varten - 200 mg - vorikonatsoli
sildenafil teva pharma 20 mg tabletti, kalvopäällysteinen
teva pharma b.v. - sildenafili citras - tabletti, kalvopäällysteinen - 20 mg - sildenafiili
ganciclovir oresund pharma 500 mg kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos
oresund pharma aps - ganciclovir sodium - kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos - 500 mg - gansikloviiri
kefavet vet 50 mg/ml rakeet oraalisuspensiota varten
orion corporation - cefalexinum monohydricum - rakeet oraalisuspensiota varten - 50 mg/ml - kefaleksiini
canesoral 150 mg kapseli, kova
bayer oy - fluconazolum - kapseli, kova - 150 mg - flukonatsoli
amoxicillin mip pharma 500 mg tabletti
mip pharma gmbh - amoxicillin trihydrate - tabletti - 500 mg - amoksisilliini
amoxicillin mip pharma 1000 mg tabletti
mip pharma gmbh - amoxicillin trihydrate - tabletti - 1000 mg - amoksisilliini
tenofovir disoproxil accordpharma 245 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - tenofovir disoproxil fumarate - tabletti, kalvopäällysteinen - 245 mg - tenofoviiridisoproksiili